Skip to main content
Top

25-04-2024 | Bariatric Surgery | Original Contributions

The Impact of Metabolic Bariatric Surgery on Cardiovascular Diseases in Patients with Metabolic Dysfunction–Associated Steatotic Liver Disease

Authors: Ali Esparham, Saeed Shoar, Ali Mehri, Zhamak Khorgami, Venkat R. Modukuru

Published in: Obesity Surgery

Login to get access

Abstract

Purpose

There is a strong association between metabolic dysfunction–associated steatotic liver disease (MASLD) and obesity which are both important risk factors for cardiovascular diseases (CVDs). The current study aimed to assess the association of MBS with different CVDs in patients with MASLD.

Materials and Methods

The National Inpatient Sample (NIS) database from 2016 to 2020 were analyzed by using ICD-10 codes. A propensity score matching in a 1:1 ratio was done to match the MBS and non-MBS groups.

Results

After weighted analysis, 1,124,155 and 68,215 patients were included in non-MBS and MBS groups, respectively. MBS was associated with significantly lower risk of hospitalization for coronary artery disease (OR 0.633 (0.569–0.703), p value < 0.001), acute myocardial infarction (OR 0.606 (0.523–0.701), p value < 0.001), percutaneous coronary intervention (OR 0.578 (0.489–0.682), p value < 0.001), and thrombolysis (OR 0.765 (0.589–0.993), p value = 0.044) compared to the non-MBS group in patients with MASLD. Furthermore, MBS was associated with 52% reduced risk of hospitalization for hemorrhagic stroke in patients with MASLD (OR 0.481, 95% CI 0.337–0.686, p value < 0.001). However, ischemic stroke was not significant between the two groups (OR 1.108 (0.905–1.356), p value = 0.322). In addition, MBS was associated with 63% and 60% reduced risk of hospitalization for heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) in patients with MASLD (OR 0.373, 95% CI 0.300–0.465 and OR 0.405, 95% CI 0.325–0.504, p value < 0.001 for both), respectively.

Conclusion

The current study showed that MBS is significantly associated with a reduced risk of hospitalization for CVD in patients with MASLD.

Graphical Abstract

Appendix
Available only for authorised users
Literature
2.
go back to reference Mundi MS, Velapati S, Patel J, et al. Evolution of NAFLD and its management. Nutr Clin Pract. 2020;35(1):72–84.CrossRefPubMed Mundi MS, Velapati S, Patel J, et al. Evolution of NAFLD and its management. Nutr Clin Pract. 2020;35(1):72–84.CrossRefPubMed
3.
go back to reference Pouwels S, Sakran N, Graham Y, et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022;22(1):63.CrossRefPubMedPubMedCentral Pouwels S, Sakran N, Graham Y, et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022;22(1):63.CrossRefPubMedPubMedCentral
4.
go back to reference Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851–61.CrossRefPubMed Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851–61.CrossRefPubMed
5.
go back to reference Lopez AD, Mathers CD. Measuring the global burden of disease and epidemiological transitions: 2002–2030. Ann Trop Med Parasitol. 2006;100(5–6):481–99.CrossRefPubMed Lopez AD, Mathers CD. Measuring the global burden of disease and epidemiological transitions: 2002–2030. Ann Trop Med Parasitol. 2006;100(5–6):481–99.CrossRefPubMed
7.
go back to reference Koliaki C, Liatis S, Kokkinos A. Obesity and cardiovascular disease: revisiting an old relationship. Metabolism. 2019;92:98–107.CrossRefPubMed Koliaki C, Liatis S, Kokkinos A. Obesity and cardiovascular disease: revisiting an old relationship. Metabolism. 2019;92:98–107.CrossRefPubMed
8.
go back to reference Chen B, Tang WHW, Rodriguez M, et al. NAFLD in cardiovascular diseases: a contributor or comorbidity? Semin Liver Dis. 2022;42(4):465–74.CrossRefPubMed Chen B, Tang WHW, Rodriguez M, et al. NAFLD in cardiovascular diseases: a contributor or comorbidity? Semin Liver Dis. 2022;42(4):465–74.CrossRefPubMed
9.
go back to reference Duell PB, Welty FK, Miller M, et al. Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42(6):e168–85.CrossRefPubMed Duell PB, Welty FK, Miller M, et al. Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2022;42(6):e168–85.CrossRefPubMed
10.
go back to reference Targher G, Corey KE, Byrne CD. NAFLD, and cardiovascular and cardiac diseases: factors influencing risk, prediction and treatment. Diabetes Metab. 2021;47(2):101215.CrossRefPubMed Targher G, Corey KE, Byrne CD. NAFLD, and cardiovascular and cardiac diseases: factors influencing risk, prediction and treatment. Diabetes Metab. 2021;47(2):101215.CrossRefPubMed
11.
go back to reference Chan WK, Chuah KH, Rajaram RB, et al. Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review. J Obes Metab Syndr. 2023;32(3):197–213.CrossRefPubMedPubMedCentral Chan WK, Chuah KH, Rajaram RB, et al. Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review. J Obes Metab Syndr. 2023;32(3):197–213.CrossRefPubMedPubMedCentral
12.
go back to reference van Veldhuisen SL, Gorter TM, van Woerden G, et al. Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis. Eur Heart J. 2022;43(20):1955–69.CrossRefPubMedPubMedCentral van Veldhuisen SL, Gorter TM, van Woerden G, et al. Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis. Eur Heart J. 2022;43(20):1955–69.CrossRefPubMedPubMedCentral
13.
go back to reference Bower G, Toma T, Harling L, et al. Bariatric surgery and non-alcoholic fatty liver disease: a systematic review of liver biochemistry and histology. Obes Surg. 2015;25(12):2280–9.CrossRefPubMed Bower G, Toma T, Harling L, et al. Bariatric surgery and non-alcoholic fatty liver disease: a systematic review of liver biochemistry and histology. Obes Surg. 2015;25(12):2280–9.CrossRefPubMed
14.
go back to reference Cusi K, Isaacs S, Barb D, et al. American association of clinical endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the american association for the study of liver diseases (AASLD). Endocr Pract. 2022;28(5):528–62.CrossRefPubMed Cusi K, Isaacs S, Barb D, et al. American association of clinical endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the american association for the study of liver diseases (AASLD). Endocr Pract. 2022;28(5):528–62.CrossRefPubMed
15.
go back to reference Aminian A, Al-Kurd A, Wilson R, et al. Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis. JAMA. 2021;326(20):2031–42.CrossRefPubMedPubMedCentral Aminian A, Al-Kurd A, Wilson R, et al. Association of bariatric surgery with major adverse liver and cardiovascular outcomes in patients with biopsy-proven nonalcoholic steatohepatitis. JAMA. 2021;326(20):2031–42.CrossRefPubMedPubMedCentral
16.
go back to reference Elsaid MI, Li Y, Bridges JFP, et al. Association of bariatric surgery with cardiovascular outcomes in adults with severe obesity and nonalcoholic fatty liver disease. JAMA Netw Open. 2022;5(10):e2235003.CrossRefPubMedPubMedCentral Elsaid MI, Li Y, Bridges JFP, et al. Association of bariatric surgery with cardiovascular outcomes in adults with severe obesity and nonalcoholic fatty liver disease. JAMA Netw Open. 2022;5(10):e2235003.CrossRefPubMedPubMedCentral
17.
go back to reference Krishnan A, Hadi Y, Alqahtani SA, et al. Cardiovascular outcomes and mortality after bariatric surgery in patients with nonalcoholic fatty liver disease and obesity. JAMA Netw Open. 2023;6(4):e237188.CrossRefPubMedPubMedCentral Krishnan A, Hadi Y, Alqahtani SA, et al. Cardiovascular outcomes and mortality after bariatric surgery in patients with nonalcoholic fatty liver disease and obesity. JAMA Netw Open. 2023;6(4):e237188.CrossRefPubMedPubMedCentral
18.
go back to reference Hirode G, Saab S, Wong RJ. Trends in the burden of chronic liver disease among hospitalized US adults. JAMA Network Open. 2020;3(4):e201997-e.CrossRef Hirode G, Saab S, Wong RJ. Trends in the burden of chronic liver disease among hospitalized US adults. JAMA Network Open. 2020;3(4):e201997-e.CrossRef
19.
go back to reference Minhas AMK, Bhopalwala HM, Dewaswala N, et al. Association of non-alcoholic fatty liver disease with in-hospital outcomes in primary heart failure hospitalizations with reduced or preserved ejection fraction. Current Problems Cardiol. 2022;48:101199.CrossRef Minhas AMK, Bhopalwala HM, Dewaswala N, et al. Association of non-alcoholic fatty liver disease with in-hospital outcomes in primary heart failure hospitalizations with reduced or preserved ejection fraction. Current Problems Cardiol. 2022;48:101199.CrossRef
20.
21.
go back to reference Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10(6):330–44.CrossRefPubMed Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10(6):330–44.CrossRefPubMed
22.
go back to reference Kim D, Touros A, Kim WR. Nonalcoholic fatty liver disease and metabolic syndrome. Clin Liver Dis. 2018;22(1):133–40.CrossRefPubMed Kim D, Touros A, Kim WR. Nonalcoholic fatty liver disease and metabolic syndrome. Clin Liver Dis. 2018;22(1):133–40.CrossRefPubMed
23.
go back to reference Golabi P, Otgonsuren M, de Avila L, et al. Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD). Medicine. 2018;97(13):e0214.CrossRefPubMedPubMedCentral Golabi P, Otgonsuren M, de Avila L, et al. Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD). Medicine. 2018;97(13):e0214.CrossRefPubMedPubMedCentral
24.
go back to reference Elsaid MI, Bridges JF, Li N, et al. Metabolic syndrome severity predicts mortality in nonalcoholic fatty liver disease. Gastro Hep Advances. 2022;1(3):445–56.CrossRef Elsaid MI, Bridges JF, Li N, et al. Metabolic syndrome severity predicts mortality in nonalcoholic fatty liver disease. Gastro Hep Advances. 2022;1(3):445–56.CrossRef
25.
go back to reference Dietrich P, Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Pract Res Clin Gastroenterol. 2014;28(4):637–53.CrossRefPubMed Dietrich P, Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Pract Res Clin Gastroenterol. 2014;28(4):637–53.CrossRefPubMed
26.
go back to reference Yki-Järvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014;2(11):901–10.CrossRefPubMed Yki-Järvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014;2(11):901–10.CrossRefPubMed
27.
go back to reference Lazarus JV, Mark HE, Colombo M, et al. A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach. Aliment Pharmacol Ther. 2022;55(2):234–43.CrossRefPubMed Lazarus JV, Mark HE, Colombo M, et al. A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach. Aliment Pharmacol Ther. 2022;55(2):234–43.CrossRefPubMed
28.
go back to reference Hannah WN Jr, Harrison SA. Effect of weight loss, diet, exercise, and bariatric surgery on nonalcoholic fatty liver disease. Clin Liver Dis. 2016;20(2):339–50.CrossRefPubMed Hannah WN Jr, Harrison SA. Effect of weight loss, diet, exercise, and bariatric surgery on nonalcoholic fatty liver disease. Clin Liver Dis. 2016;20(2):339–50.CrossRefPubMed
29.
go back to reference Keating SE, Hackett DA, George J, et al. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol. 2012;57(1):157–66.CrossRefPubMed Keating SE, Hackett DA, George J, et al. Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol. 2012;57(1):157–66.CrossRefPubMed
30.
go back to reference Romero-Gómez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017;67(4):829–46.CrossRefPubMed Romero-Gómez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017;67(4):829–46.CrossRefPubMed
31.
go back to reference Mummadi RR, Kasturi KS, Chennareddygari S, et al. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2008;6(12):1396–402.CrossRefPubMed Mummadi RR, Kasturi KS, Chennareddygari S, et al. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2008;6(12):1396–402.CrossRefPubMed
32.
go back to reference Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA. 2012;307(1):56–65.CrossRefPubMed Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA. 2012;307(1):56–65.CrossRefPubMed
33.
go back to reference Lassailly G, Caiazzo R, Ntandja-Wandji LC, et al. Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis. Gastroenterol. 2020;159(4):1290-301.e5.CrossRef Lassailly G, Caiazzo R, Ntandja-Wandji LC, et al. Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis. Gastroenterol. 2020;159(4):1290-301.e5.CrossRef
34.
go back to reference Fakhry TK, Mhaskar R, Schwitalla T, et al. Bariatric surgery improves nonalcoholic fatty liver disease: a contemporary systematic review and meta-analysis. Surg Obes Relat Dis. 2019;15(3):502–11.CrossRefPubMed Fakhry TK, Mhaskar R, Schwitalla T, et al. Bariatric surgery improves nonalcoholic fatty liver disease: a contemporary systematic review and meta-analysis. Surg Obes Relat Dis. 2019;15(3):502–11.CrossRefPubMed
35.
go back to reference Oliveras A, Molina L, Goday A, et al. Effect of bariatric surgery on cardiac structure and function in obese patients: role of the renin-angiotensin system. The Journal of Clinical Hypertension. 2021;23(1):181–92.CrossRefPubMed Oliveras A, Molina L, Goday A, et al. Effect of bariatric surgery on cardiac structure and function in obese patients: role of the renin-angiotensin system. The Journal of Clinical Hypertension. 2021;23(1):181–92.CrossRefPubMed
36.
go back to reference Villarreal-Calderón JR, Cuéllar RX, Ramos-González MR, et al. Interplay between the adaptive immune system and insulin resistance in weight loss induced by bariatric surgery. Oxid Med Cell Longev. 2019;2019:3940739.CrossRefPubMedPubMedCentral Villarreal-Calderón JR, Cuéllar RX, Ramos-González MR, et al. Interplay between the adaptive immune system and insulin resistance in weight loss induced by bariatric surgery. Oxid Med Cell Longev. 2019;2019:3940739.CrossRefPubMedPubMedCentral
37.
go back to reference Seyyedi J, Alizadeh S. Effect of surgically induced weight loss on biomarkers of endothelial dysfunction: a systematic review and meta-analysis. Obes Surg. 2020;30(9):3549–60.CrossRefPubMed Seyyedi J, Alizadeh S. Effect of surgically induced weight loss on biomarkers of endothelial dysfunction: a systematic review and meta-analysis. Obes Surg. 2020;30(9):3549–60.CrossRefPubMed
38.
go back to reference Esparham A, Shoar S, Kheradmand HR, et al. The impact of bariatric surgery on cardiac structure, and systolic and diastolic function in patients with obesity: a systematic review and meta-analysis. Obes Surg. 2023;33(1):345–61.CrossRefPubMed Esparham A, Shoar S, Kheradmand HR, et al. The impact of bariatric surgery on cardiac structure, and systolic and diastolic function in patients with obesity: a systematic review and meta-analysis. Obes Surg. 2023;33(1):345–61.CrossRefPubMed
39.
go back to reference Esparham A, Roohi S, Ahmadyar S, Dalili A, Nelson P, Khorgami Z. Impact of bariatric surgery on carotid intima-media thickness, flow-mediated dilation, and nitrite-mediated dilation: a systematic review and meta-analysis. Surg Obesity Related Diseases. 2023;19:1188.CrossRef Esparham A, Roohi S, Ahmadyar S, Dalili A, Nelson P, Khorgami Z. Impact of bariatric surgery on carotid intima-media thickness, flow-mediated dilation, and nitrite-mediated dilation: a systematic review and meta-analysis. Surg Obesity Related Diseases. 2023;19:1188.CrossRef
Metadata
Title
The Impact of Metabolic Bariatric Surgery on Cardiovascular Diseases in Patients with Metabolic Dysfunction–Associated Steatotic Liver Disease
Authors
Ali Esparham
Saeed Shoar
Ali Mehri
Zhamak Khorgami
Venkat R. Modukuru
Publication date
25-04-2024
Publisher
Springer US
Published in
Obesity Surgery
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-024-07238-w
Webinar | 06-02-2024 | 20:00 (CET)

Mastering chronic pancreatitis pain: A multidisciplinary approach and practical solutions

Severe pain is the most common symptom of chronic pancreatitis. In this webinar, experts share the latest insights in pain management for chronic pancreatitis patients. Experts from a range of disciplines discuss pertinent cases and provide practical suggestions for use within clinical practice.

Sponsored by: Viatris

Developed by: Springer Healthcare